Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC next week will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> More Than Half Of People With HIV Now Have Access To Treatment, UNAIDS Says 20/07/2017 William New For the first time, more than half of people in the world living with HIV have access to treatment, UNAIDS said in a report released today in Geneva. In addition, AIDS-related deaths have been nearly cut in half since 2005, it said. As of 2016, nearly 20 million people were living with HIV. Continue reading -> Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Will The Money Keep Rolling?: Innovative Global Health Financing And Governance 26/05/2017 Mara Pillinger We are in a liminal moment for global health financing. The “golden age” of increasing donor funding is clearly over, arrested by the 2008 financial crisis. But while donor contributions are no longer climbing, they have not been falling, either. And it is possible this status quo will hold… But it’s equally possible that this is just the pause before the roller-coaster drops. Considering that Gavi, the Global Fund, and the World Bank will all be launching another replenishment round in 2019—and given the uncertainty surrounding US foreign aid commitments and post-polio financing—that drop may prove very steep indeed. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> More Than Half Of People With HIV Now Have Access To Treatment, UNAIDS Says 20/07/2017 William New For the first time, more than half of people in the world living with HIV have access to treatment, UNAIDS said in a report released today in Geneva. In addition, AIDS-related deaths have been nearly cut in half since 2005, it said. As of 2016, nearly 20 million people were living with HIV. Continue reading -> Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Will The Money Keep Rolling?: Innovative Global Health Financing And Governance 26/05/2017 Mara Pillinger We are in a liminal moment for global health financing. The “golden age” of increasing donor funding is clearly over, arrested by the 2008 financial crisis. But while donor contributions are no longer climbing, they have not been falling, either. And it is possible this status quo will hold… But it’s equally possible that this is just the pause before the roller-coaster drops. Considering that Gavi, the Global Fund, and the World Bank will all be launching another replenishment round in 2019—and given the uncertainty surrounding US foreign aid commitments and post-polio financing—that drop may prove very steep indeed. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
Access To Medicines Foundation Details Methodology For 2018 AMR Benchmark 24/08/2017 William New The Amsterdam-based Access to Medicines Foundation today published the methodology it will use for its 2018 framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance, addressing the rising the global problem of overuse of antibiotics leading to resistance with few new ones in the pipeline. Continue reading -> The Case For Nations To Act On Medicines Access 23/07/2017 William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> More Than Half Of People With HIV Now Have Access To Treatment, UNAIDS Says 20/07/2017 William New For the first time, more than half of people in the world living with HIV have access to treatment, UNAIDS said in a report released today in Geneva. In addition, AIDS-related deaths have been nearly cut in half since 2005, it said. As of 2016, nearly 20 million people were living with HIV. Continue reading -> Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Will The Money Keep Rolling?: Innovative Global Health Financing And Governance 26/05/2017 Mara Pillinger We are in a liminal moment for global health financing. The “golden age” of increasing donor funding is clearly over, arrested by the 2008 financial crisis. But while donor contributions are no longer climbing, they have not been falling, either. And it is possible this status quo will hold… But it’s equally possible that this is just the pause before the roller-coaster drops. Considering that Gavi, the Global Fund, and the World Bank will all be launching another replenishment round in 2019—and given the uncertainty surrounding US foreign aid commitments and post-polio financing—that drop may prove very steep indeed. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
The Case For Nations To Act On Medicines Access 23/07/2017 William New NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead? Continue reading -> More Than Half Of People With HIV Now Have Access To Treatment, UNAIDS Says 20/07/2017 William New For the first time, more than half of people in the world living with HIV have access to treatment, UNAIDS said in a report released today in Geneva. In addition, AIDS-related deaths have been nearly cut in half since 2005, it said. As of 2016, nearly 20 million people were living with HIV. Continue reading -> Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Will The Money Keep Rolling?: Innovative Global Health Financing And Governance 26/05/2017 Mara Pillinger We are in a liminal moment for global health financing. The “golden age” of increasing donor funding is clearly over, arrested by the 2008 financial crisis. But while donor contributions are no longer climbing, they have not been falling, either. And it is possible this status quo will hold… But it’s equally possible that this is just the pause before the roller-coaster drops. Considering that Gavi, the Global Fund, and the World Bank will all be launching another replenishment round in 2019—and given the uncertainty surrounding US foreign aid commitments and post-polio financing—that drop may prove very steep indeed. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
More Than Half Of People With HIV Now Have Access To Treatment, UNAIDS Says 20/07/2017 William New For the first time, more than half of people in the world living with HIV have access to treatment, UNAIDS said in a report released today in Geneva. In addition, AIDS-related deaths have been nearly cut in half since 2005, it said. As of 2016, nearly 20 million people were living with HIV. Continue reading -> Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Will The Money Keep Rolling?: Innovative Global Health Financing And Governance 26/05/2017 Mara Pillinger We are in a liminal moment for global health financing. The “golden age” of increasing donor funding is clearly over, arrested by the 2008 financial crisis. But while donor contributions are no longer climbing, they have not been falling, either. And it is possible this status quo will hold… But it’s equally possible that this is just the pause before the roller-coaster drops. Considering that Gavi, the Global Fund, and the World Bank will all be launching another replenishment round in 2019—and given the uncertainty surrounding US foreign aid commitments and post-polio financing—that drop may prove very steep indeed. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Will The Money Keep Rolling?: Innovative Global Health Financing And Governance 26/05/2017 Mara Pillinger We are in a liminal moment for global health financing. The “golden age” of increasing donor funding is clearly over, arrested by the 2008 financial crisis. But while donor contributions are no longer climbing, they have not been falling, either. And it is possible this status quo will hold… But it’s equally possible that this is just the pause before the roller-coaster drops. Considering that Gavi, the Global Fund, and the World Bank will all be launching another replenishment round in 2019—and given the uncertainty surrounding US foreign aid commitments and post-polio financing—that drop may prove very steep indeed. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Will The Money Keep Rolling?: Innovative Global Health Financing And Governance 26/05/2017 Mara Pillinger We are in a liminal moment for global health financing. The “golden age” of increasing donor funding is clearly over, arrested by the 2008 financial crisis. But while donor contributions are no longer climbing, they have not been falling, either. And it is possible this status quo will hold… But it’s equally possible that this is just the pause before the roller-coaster drops. Considering that Gavi, the Global Fund, and the World Bank will all be launching another replenishment round in 2019—and given the uncertainty surrounding US foreign aid commitments and post-polio financing—that drop may prove very steep indeed. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
Will The Money Keep Rolling?: Innovative Global Health Financing And Governance 26/05/2017 Mara Pillinger We are in a liminal moment for global health financing. The “golden age” of increasing donor funding is clearly over, arrested by the 2008 financial crisis. But while donor contributions are no longer climbing, they have not been falling, either. And it is possible this status quo will hold… But it’s equally possible that this is just the pause before the roller-coaster drops. Considering that Gavi, the Global Fund, and the World Bank will all be launching another replenishment round in 2019—and given the uncertainty surrounding US foreign aid commitments and post-polio financing—that drop may prove very steep indeed. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts
World Health Assembly 70: A Spectator’s Guide To Program/Budget, Election, Polio Transition 22/05/2017 Mara Pillinger The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading -> Posts navigation Older postsNewer posts